Iovance Biotherapeutics, Inc. (IOVA) News
Filter IOVA News Items
IOVA News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
IOVA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest IOVA News From Around the Web
Below are the latest news stories about IOVANCE BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate IOVA as an investment opportunity.
3 Mid-Cap Stocks That Could Take Off in 2025Mid-cap stocks represent companies valued at between $2 billion and $10 billion. If they give investors a reason to be bullish on their growth prospects or show that they're on the right path, these types of investments can double in value and be 10-baggers in the long run. Iovance Biotherapeutics has a market cap of $2.3 billion. |
Exploring 3 High Growth Tech Stocks In The United StatesOver the last 7 days, the United States market has experienced a 2.8% drop, yet it remains up by 24% over the past year with earnings forecasted to grow by 15% annually. In this context of fluctuating performance and promising growth prospects, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in an evolving technological landscape. |
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher TodayOn the back of a glowing analyst recommendation, Iovance Biotherapeutics's (NASDAQ: IOVA) shares closed Thursday more than 5% higher in price. The entity delivering the good news was financial services company Stifel, whose analyst Benjamin Burnett tagged Iovance as its top stock pick in the biotech sector for 2025. Almost needless to say, Burnett reiterated his buy recommendation on the shares. |
Why Iovance Biotherapeutics Inc. (IOVA) Is SkyrocketingWe recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other firms end 2024 stronger with impressive gains. A lackluster trading persisted throughout the last day of the year, with Wall Street’s main […] |
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 19, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 203,980 shares of Iovance’s common stock to forty-eight n |
If I Could Only Buy 3 Stocks in the Last Month of 2024, I'd Pick TheseThese windows of opportunity aren't likely to remain open for much longer. |
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?The Food and Drug Administration (FDA) approved CRISPR Therapeutics' (NASDAQ: CRSP) first treatment last December, and its successful launch could push the stock much higher. Investment bank analysts also expect Iovance Biotherapeutics (NASDAQ: IOVA) to soar in 2025. Before chasing exciting price targets, though, it's important to remember that analysts who set lofty expectations can quietly adjust them downward if things don't work out. |
Prediction: This Stock Will Beat the Market in 2025It hasn't been a great year for Iovance Biotherapeutics (NASDAQ: IOVA), an innovative mid-cap biotech company. Let's look deeper into how Iovance Biotherapeutics could pull that off. It is manufactured using patients' own TIL cells, which can identify and kill cancer cells. |
3 Monster Stocks to Hold for the Next 10 YearsJust be ready to ride out some inevitable turbulence along the way. |
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a favorite amongst institutional investors who own 63%Key Insights Institutions' substantial holdings in Iovance Biotherapeutics implies that they have significant influence... |